Savara (SVRA) Change in Acquisitions & Divestments (2018 - 2026)
Savara (SVRA) posted quarterly Change in Acquisitions & Divestments of $13.1 million for Q1 2026, down 70.42% year-over-year from $44.4 million in Q1 2025, and up 108.84% quarter-over-quarter from -$148.5 million in Q4 2025.
Analysis
Savara (SVRA) Change in Acquisitions & Divestments (2018 - 2026) Analysis & Trends
Savara (SVRA) has reported Change in Acquisitions & Divestments for 9 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Acquisitions & Divestments fell 70.42% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at -$27.0 million (down 116.07% YoY), while the FY2025 annual figure was $4.3 million, down 97.41% from the prior year.
- Change in Acquisitions & Divestments rose to $13.1 million in Q1 2026 per SVRA's latest filing, from -$148.5 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $119.5 million in Q4 2022 and bottomed at -$148.5 million in Q4 2025.
- Historically, Change in Acquisitions & Divestments has averaged $30.0 million across 5 years, with a median of $40.6 million in 2024.
- Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments surged 300.3% — and 2025, when it slumped 397.34%.
- Savara's Change in Acquisitions & Divestments stood at $119.5 million in 2022, then plunged by 62.01% to $45.4 million in 2023, then increased by 10.02% to $49.9 million in 2024, then plunged by 397.34% to -$148.5 million in 2025, then soared by 108.84% to $13.1 million in 2026.
- Business Quant data shows SVRA's Change in Acquisitions & Divestments at $13.1 million in Q1 2026, -$148.5 million in Q4 2025, and $44.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.20 Mn |
| Mar 31, 2026 | 25.70 Mn |
| Dec 31, 2025 | 29.40 Mn |
| Sep 30, 2025 | 44.40 Mn |
| Jun 30, 2025 | 64.00 Mn |
| Mar 31, 2025 | 44.40 Mn |
| Dec 31, 2024 | 49.95 Mn |
| Sep 30, 2024 | 40.55 Mn |
| Jun 30, 2024 | 33.00 Mn |
| Mar 31, 2024 | 41.50 Mn |
| Dec 31, 2023 | 45.40 Mn |
| Sep 30, 2023 | 38.00 Mn |
| Jun 30, 2023 | 30.00 Mn |
| Mar 31, 2023 | 24.00 Mn |
| Dec 31, 2022 | 14.20 Mn |
| Sep 30, 2022 | 33.00 Mn |
| Jun 30, 2022 | 25.20 Mn |
| Mar 31, 2022 | 58.39 Mn |
| Dec 31, 2021 | 15.60 Mn |
| Sep 30, 2021 | 34.59 Mn |